B
INFI

Bridgeworth’s Infinity Pharmaceuticals, Inc. INFI Stock Holding History

Bridgeworth’s Portfolio INFI Stock Details INFI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-1,837
Closed -$3K – 581
2018
Q2 		$3K Buy
+1,837
New +$3.71K ﹤0.01% 555

Other funds holding INFI

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
NC
Northpointe Capital Bloomfield Hills, Michigan $258M AUM 1.97% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

Bridgeworth's INFI Position: Q3 2018 in Review

Bridgeworth sold out of Infinity Pharmaceuticals, Inc. (INFI) in Q3 2018, closing a stake of 1,837 shares — an estimated $3K sold.

Bridgeworth first reported a position in INFI in Q2 2018 and held it in 1 quarter. The position peaked at $3K in Q2 2018. 63 funds tracked by Wall St. Rank hold INFI as of Q3 2018.

  • Bridgeworth reported no remaining Infinity Pharmaceuticals, Inc. position as of Q3 2018 after selling out during the quarter.
  • Bridgeworth sold 1,837 Infinity Pharmaceuticals, Inc. shares in Q3 2018, an estimated $3K.
  • Bridgeworth first reported a position in Infinity Pharmaceuticals, Inc. in Q2 2018 and held it in 1 quarter.
  • Bridgeworth's Infinity Pharmaceuticals, Inc. position peaked at $3K in Q2 2018.
  • 63 funds tracked by Wall St. Rank held Infinity Pharmaceuticals, Inc. as of Q3 2018.

Based on Bridgeworth's 13F filing for Q3 2018, filed 13 Nov 2018.